reports
Information relative au nombre total de droits de vote et d’actions co...
Information relative au nombre total de droits de vote et d’actions composant le capital social Communiqué de Presse Dijon, le 20 novembre 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant son capital social au 31 octobre 2024. DateNombre d’actions Composant le capitalSocial (1)Nombre de droits d...
Crossject’s ZENEO® Auto-Injector's usability further demonstrated in e...
Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack conditions. Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without any handling problem.Study underscores ZENEO® Midazolam’s usability in extreme, high-ri...
Crossject annonce des progrès majeurs dans la fabrication de son trait...
Crossject annonce des progrès majeurs dans la fabrication de son traitement d’urgence ZEPIZURE®, pour la prise en charge des crises d’épilepsie, à l’approche du dépôt d’une demande d’autorisation d’utilisation d’urgence aux États-Unis. Le lot de produits annoncé en juillet a permis de recueillir davantage de données de stabilité, qui au premier trimestre 2025 soutiendront directement la stabilité requise de six mois.Crossject prévoit de déposer une demande d’autorisation d’utilisation d’urgence (EUA) au début de l’année prochaine et anticipe une réponse positive de la FDA dans un délai cou...
Crossject reports strong manufacturing progress with its epilepsy resc...
Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafterCrossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that year Dijon, Franc...
Crossject : Information relative au nombre total de droits de vote et ...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 7 octobre 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant s...
Crossject : Information relative au nombre total de droits de vote et ...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 7 octobre 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant s...
Crossject : Information relative au nombre total de droits de vote et ...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 7 octobre 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant s...
- Fabrice Farigoule
H1 24: not yet meaningful (Crossject)
H1 24: not yet meaningful EPS CHANGE CHANGE IN EPS 2024 : € (0.24) vs (0.12) ns 2025 : € 0.02 vs 0.02 We have fine-tuned our forecasts for the current year. This plays a very minor role for Crossject since the story is that of the future market launches of the company’s NTEs (New Therapeutic Entities) as from FY25 and has no impact on our valuation. For the sake of detailing, the main difference with our previous FY24e EPS lies in a likely lower level of capitalised production than we expec...
Crossject announces its eligibility for France’s PEA-PME investment sc...
Crossject announces its eligibility for France’s PEA-PME investment scheme Enables French retail investors to buy securities under preferential tax conditions Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®, today confirms its eligibility for PEA-PME, a French government investment scheme which enables retail investors to acquire a portfolio of European securities whilst benefiting from preferential tax conditions. This fram...
- Fabrice Farigoule
H1 24: no real surprise, but a glimpse of disappointment
H1 24: no real surprise, but a glimpse of disappointment EARNINGS/SALES RELEASES The company released its H1 24 numbers and reminded the milestones achieved over the past few months. Even if we still believe in the case, we are a bit perplexed about the ability of the group to have its products reach the market without another financing round. We also found that management shows a degree cautiousness with respect to the timing of such a launch. Whether this is a just a way to make sure not to ...
- Jean-François Granjon
- Louis Boujard
- CFA
- Jean-François Granjon
- Louis Boujard
- CFA
- Martial Descoutures
- Oussema Denguir
Crossject : Calendrier confirmé pour Zepizure
>Une publication du S1 24 très classique - La société a publié hier ses résultats du S1 2024. Les produits d’exploitation s’élèvent à 5.8 M€ (vs 7.9 M€ en 2023) dont 3.3 M€ provenant de ses avancées réglementaires avec la BARDA, légèrement en hausse par rapport au S1 2023 (3.2 M€). Les investissements en R&D restent stables et la perte d’exploitation a marginalement augmenté (-6.7 M€ vs -6.5 M€ au S1 2023). Un P&L classique. Au niveau du bilan, Crossject a émis u...
- Martial Descoutures
- Oussema Denguir
Crossject : Calendar confirmed for Zepizure
>A very typical results publication for H1 2024 - Crossject reported its Q1 2024 results yesterday. Operating income totalled € 5.8m (vs € 7.9m in 2023), of which € 3.3m came from its regulatory advances with BARDA, slightly up compared to H1 2023 (€ 3.2m). R&D investments remained stable and the operating loss widened marginally (-€ 6.7m vs -€ 6.5m in H1 2023). A classic P&L Regarding the balance sheet, Crossject issued a convertible and/or redeemable bond in t...
Crossject reports financial results and business highlights for the fi...
Crossject reports financial results and business highlights for the first six months of 2024 Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the Emergency Use Authorization for its epilepsy rescue therapy in early 2025 Dijon, France, September 23, 2024 18:00 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emer...
Crossject to report first-half 2024 financial results and host webcast...
Crossject to report first-half 2024 financial results and host webcast on September 23, 2024 Dijon, France, 17 September, 2024 - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®, will report its financial results for the six months ended June 30, 2024, as scheduled on Monday, September 23. In addition, at 18:00 CET that day, CEO Patrick Alexandre will provide a commentary on the company’s strategic priorities during a webcast and be available for questions...
Crossject publiera ses résultats financiers du premier semestre et org...
Crossject publiera ses résultats financiers du premier semestre et organisera un webcast le 23 Septembre 2024 Dijon, France, 17 septembre 2024 - Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique spécialisée dans le développement de médicaments pour les situations d'urgence exploitant son auto-injecteur sans aiguille primé ZENEO®, publiera ses résultats financiers pour le semestre clos le 30 juin 2024, comme prévu le lundi 23 septembre. En outre, à 18h00 CET ce jour-là, le PDG Patrick Alexandre commentera les priorités stratégiques de l'entreprise au cours d'un web...
Crossject to Present at the H.C. Wainwright 26th Annual Global Investm...
Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 Press Release Dijon, France August 22, 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®, announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th,...
Crossject participera à la 26ème Annual Global Investment Conference d...
Crossject participera à la 26ème Annual Global Investment Conference de H.C. Wainwright, 9 au 11 septembre 2024 Communiqué de Presse Dijon, France, le 22 août 2024 07:30 CET — Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe des médicaments dédiés aux situations d'urgence, administrables grâce à son auto-injecteur sans aiguille primé ZENEO®, annonce qu'il participera virtuellement et prendra part à des réunions individuelles avec des investisseurs lors de la 26e Conférence Annuelle sur l'Investissement Global organisée par H.C. Wainw...
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Prep...
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations for U.S. commercialization of ZEPIZURE®Reinforces and de-risks pre-commercial activities ahead of submitting marketing authorization application for ZEPIZURE® epilepsy rescue treatment in the U.S. Dijon, France August 19, 2024 17:30 CET-- Crossjec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.